Dr. Ibrahim A. Al-Homood
Dr. Ibrahim AI-Homood is a consultant rheumatologist and chairman of medical specialities I department at King Fahad Medical City (KFMC), Riyadh, Saudi Arabia. He is also a director I of rheumatology fellowship program at KFMC. He is a chairman of Saudi medical license I exam council. He has several publications in scientific peer review journals
1- Rudwaleit M, et al. The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis Rheum. 2009 Mar;60(3):717-27.
3- Haibel H, et al. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum. 2008 Jul;58(7):1981-91
5- Deodhar A, et al. lxekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial. Lancet. 2020 Jan 4;395(10217):53-64.
2- Nikiphorou, et al. Treat to Target in Axial Spondyloarthritis. Rheum Dis Clin N Am 45 (2019) 519-535
4- Baraliakos X, et al. Efficiency of treatment with non-steroidal anti-inflammatory drugs according to current recommendations in patients with radiographic and non-radiographic axial spondyloarthritis. Rheumatology (Oxford). 2017 Jan;56(1):95-102.